David Sinclair
InvestorVenture Partner at Catalio Capital Management, LP
Boston, Massachusetts
Writes $100K – $5M checks · typically $1.5M
Find your path to David
35 people in our graph share verified history with David — schools, employers, funds. One of them is your warm intro.
About
David Sinclair is a Professor of Genetics at Harvard Medical School and Co-Director of the Paul F. Glenn Labs for the Biology of Aging, focusing on longevity and the biology of aging. He holds a BS and PhD from the University of New South Wales and completed a post-doctoral fellowship at MIT. He has co-founded numerous biotechnology companies and authored the New York Times bestseller "Lifespan."
Invests in
BiotechLongevity
Investments
Investor
Arc BioCohBarContinuum BiosciencesGenocea BioscienceIdunaImmetasJumpstart FertilityLiberty BiosecurityLife BiosciencesMetroBiotechRevere BiosensorsSenolytic TherapeuticsSirtris PharmaceuticalsSpotlight Biosciences
Per the firm's website.
Colleagues at Catalio Capital Management, LP
Network4
Investors connected to David in public investor directories — a warm-intro map.
Frequently asked questions
- Who is David Sinclair?
- David Sinclair is a Professor of Genetics at Harvard Medical School and Co-Director of the Paul F. Glenn Labs for the Biology of Aging, focusing on longevity and the biology of aging. He holds a BS and PhD from the University of New South Wales and completed a post-doctoral fellowship at MIT. He has co-founded numerous biotechnology companies and authored the New York Times bestseller "Lifespan."
- Where does David Sinclair work?
- David Sinclair is Venture Partner at Catalio Capital Management, LP.
- What does David Sinclair invest in?
- David Sinclair invests in Biotech, Longevity.
- What check size does David Sinclair write?
- David Sinclair typically writes checks of $100K – $5M.
- What companies has David Sinclair invested in?
- Investments tracked here include Arc Bio, CohBar, Continuum Biosciences, Genocea Bioscience, Iduna, Immetas, Jumpstart Fertility, Liberty Biosecurity, Life Biosciences, MetroBiotech, Revere Biosensors, Senolytic Therapeutics, and 2 more.